Thomas Steffen1, Sabrina M Ebinger2, René Warschkow1,3, Cornelia Lüthi1, Bruno M Schmied1, Thomas Clerici1. 1. Department of Surgery, Cantonal Hospital of St. Gallen, 9007, St. Gallen, Switzerland. 2. Department of Surgery, Cantonal Hospital of St. Gallen, 9007, St. Gallen, Switzerland. sabrina.ebinger@gmx.ch. 3. Institute of Medical Biometry and Informatics, University of Heidelberg, 69120, Heidelberg, Germany.
Abstract
BACKGROUND: Appendiceal neuroendocrine tumors (aNET) are a common entity in routine medical care, with a rate per appendectomy as high as 0.3-0.9 %. Considering the relatively young age at diagnosis for these patients, exact information about the long-term prognosis of aNET is required. Survival rates vary substantially between 71 and 100 % and are mostly limited to 5 years. This investigation assessed the long-term mortality rates of patients who underwent aNET resections at fifteen hospitals. METHODS: Between 1990 and 2003, the 10-year survival rates of 79 patients were analyzed using risk-adjusted Cox proportional hazard regression models adjusted for population-based baseline mortality. Additionally, prognostic factors for the oncologic outcomes were assessed. RESULTS: The median follow-up of all patients was 12.1 and 13.7 years for those alive. All patients underwent curative R0 resections. No distant metastases were diagnosed. A total of 31 (39.2 %), 29 (36.7 %), 18 (22.8 %), and 1 (1.3 %) patients had stage I, IIA, IIB, and IIIB aNET, respectively, according to the latest classification by the European Neuroendocrine Tumor Society. The 10-year overall and relative survival rates were 83.6 % (95 % CI 75.5-92.6 %) and 96.7 % (95 % CI 87.5-107 %), respectively. The 10-year relative survival rate after resection of aNET did not differ from the survival of the average national population with the same age and gender (p = 0.947). Second primary malignancies (hazard ratio of death 7.0, 95 % CI 1.6-30.6) were identified as a significant prognosticator for long-term survival. CONCLUSIONS: Long-term survival is not significantly depreciated after the curative resection of aNET.
BACKGROUND:Appendiceal neuroendocrine tumors (aNET) are a common entity in routine medical care, with a rate per appendectomy as high as 0.3-0.9 %. Considering the relatively young age at diagnosis for these patients, exact information about the long-term prognosis of aNET is required. Survival rates vary substantially between 71 and 100 % and are mostly limited to 5 years. This investigation assessed the long-term mortality rates of patients who underwent aNET resections at fifteen hospitals. METHODS: Between 1990 and 2003, the 10-year survival rates of 79 patients were analyzed using risk-adjusted Cox proportional hazard regression models adjusted for population-based baseline mortality. Additionally, prognostic factors for the oncologic outcomes were assessed. RESULTS: The median follow-up of all patients was 12.1 and 13.7 years for those alive. All patients underwent curative R0 resections. No distant metastases were diagnosed. A total of 31 (39.2 %), 29 (36.7 %), 18 (22.8 %), and 1 (1.3 %) patients had stage I, IIA, IIB, and IIIB aNET, respectively, according to the latest classification by the European Neuroendocrine Tumor Society. The 10-year overall and relative survival rates were 83.6 % (95 % CI 75.5-92.6 %) and 96.7 % (95 % CI 87.5-107 %), respectively. The 10-year relative survival rate after resection of aNET did not differ from the survival of the average national population with the same age and gender (p = 0.947). Second primary malignancies (hazard ratio of death 7.0, 95 % CI 1.6-30.6) were identified as a significant prognosticator for long-term survival. CONCLUSIONS: Long-term survival is not significantly depreciated after the curative resection of aNET.
Authors: Ursula Plöckinger; Anne Couvelard; Massimo Falconi; Anders Sundin; Ramon Salazar; Emanuel Christ; Wouter W de Herder; David Gross; Wolfram H Knapp; Ulrich P Knigge; Matthew H Kulke; Ulrich F Pape Journal: Neuroendocrinology Date: 2007-10-11 Impact factor: 4.914
Authors: S Grozinsky-Glasberg; K I Alexandraki; D Barak; V Doviner; P Reissman; G A Kaltsas; D J Gross Journal: Neuroendocrinology Date: 2012-11-22 Impact factor: 4.914
Authors: Jon Arne Søreide; Jan Terje Kvaløy; Dordi Lea; Oddvar M Sandvik; Mohammed Al-Saiddi; Torjan M Haslerud; Herish Garresori; Lars N Karlsen; Einar Gudlaugsson; Kjetil Søreide Journal: Cancer Rep (Hoboken) Date: 2021-06-08